AR126404A1 - Composiciones farmacéuticas de un anticuerpo anti pd-1 y uso de las mismas - Google Patents

Composiciones farmacéuticas de un anticuerpo anti pd-1 y uso de las mismas

Info

Publication number
AR126404A1
AR126404A1 ARP220101785A ARP220101785A AR126404A1 AR 126404 A1 AR126404 A1 AR 126404A1 AR P220101785 A ARP220101785 A AR P220101785A AR P220101785 A ARP220101785 A AR P220101785A AR 126404 A1 AR126404 A1 AR 126404A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
retifanlimab
antibody
cancer
approximately
Prior art date
Application number
ARP220101785A
Other languages
English (en)
Spanish (es)
Inventor
Krishnan Sampathkumar
Yan Zhou
Stephen James Burke
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR126404A1 publication Critical patent/AR126404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP220101785A 2021-07-09 2022-07-07 Composiciones farmacéuticas de un anticuerpo anti pd-1 y uso de las mismas AR126404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09

Publications (1)

Publication Number Publication Date
AR126404A1 true AR126404A1 (es) 2023-10-11

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101785A AR126404A1 (es) 2021-07-09 2022-07-07 Composiciones farmacéuticas de un anticuerpo anti pd-1 y uso de las mismas

Country Status (17)

Country Link
US (2) US12364756B2 (cg-RX-API-DMAC10.html)
EP (1) EP4366692A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024525566A (cg-RX-API-DMAC10.html)
KR (1) KR20240035533A (cg-RX-API-DMAC10.html)
CN (1) CN118215465A (cg-RX-API-DMAC10.html)
AR (1) AR126404A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022307332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224640A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000198A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240065A (cg-RX-API-DMAC10.html)
EC (1) ECSP24008791A (cg-RX-API-DMAC10.html)
IL (1) IL309985A (cg-RX-API-DMAC10.html)
MX (1) MX2024000268A (cg-RX-API-DMAC10.html)
PE (1) PE20240797A1 (cg-RX-API-DMAC10.html)
TW (1) TW202308694A (cg-RX-API-DMAC10.html)
WO (1) WO2023283049A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记

Also Published As

Publication number Publication date
KR20240035533A (ko) 2024-03-15
JP2024525566A (ja) 2024-07-12
PE20240797A1 (es) 2024-04-18
CA3224640A1 (en) 2023-01-12
US20230025464A1 (en) 2023-01-26
EP4366692A1 (en) 2024-05-15
CR20240065A (es) 2024-04-08
TW202308694A (zh) 2023-03-01
AU2022307332A1 (en) 2024-01-18
US20250345422A1 (en) 2025-11-13
WO2023283049A1 (en) 2023-01-12
IL309985A (en) 2024-03-01
ECSP24008791A (es) 2024-03-01
MX2024000268A (es) 2024-01-31
US12364756B2 (en) 2025-07-22
CN118215465A (zh) 2024-06-18
CO2024000198A2 (es) 2024-02-05
CL2024000077A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
AR124140A2 (es) Formulaciones de anticuerpos
Dimopoulos et al. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma
AR130402A2 (es) Formulaciones de anticuerpos anti-pdl1
AR111773A1 (es) Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
CL2023002505A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
PE20251257A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
ECSP099642A (es) Formulaciones estables de anticuerpo
CL2009002199A1 (es) Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002).
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
AR042977A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
AR108317A1 (es) Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20070116A1 (es) Formulacion de anticuerpos estables
AR081677A1 (es) Metodos y composiciones para la administracion intratecal de iduronato-2-sulfatasa, recipiente, sistema para administracion intratecal
AR095451A1 (es) Formulación de anticuerpos
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
RU2017128616A (ru) Комбинированное лекарственное средство
UY39878A (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
HRP20231229T1 (hr) Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
MX2024009079A (es) Composicion farmaceutica que comprende el conjugado anticuerpo anti-cd79b-farmaco y su uso.
Rehman et al. Ethanol and vitamin D receptor in T cell apoptosis